Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2476
Champion Homes
SKY
$5.19B
| $1.29M | ﹤0.01% |
214,800
-63,000
| -23% | -$402K |
|
2477
SELLAS Life Sciences
SLS
$2.49B
| $1.29M | ﹤0.01% |
1,481
+414
| +39% | +$360K |
|
2478
TriMas Corp
TRS
$1.39B
| $1.28M | ﹤0.01% |
61,500
+44,300
| +258% | +$956K |
|
|
HZNP
2479
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $1.28M | ﹤0.01% |
+107,900
| New | +$1.34M |
|
2480
First Hawaiian
FHB
$3.39B
| $1.28M | ﹤0.01% |
41,800
-294,690
| -88% | -$8.61M |
|
|
FNJN
2481
DELISTED
Finjan Holdings, Inc.
FNJN
| $1.27M | ﹤0.01% |
388,100
+252,400
| +186% | +$654K |
|
|
FRTX
2482
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
| $1.27M | ﹤0.01% |
1,518
+197
| +15% | +$144K |
|
|
GLOG
2483
DELISTED
GASLOG LTD
GLOG
| $1.27M | ﹤0.01% |
83,400
+70,900
| +567% | +$998K |
|
|
IMBI
2484
DELISTED
iMedia Brands, Inc. Class A Common Stock
IMBI
| $1.26M | ﹤0.01% |
126,086
+9,680
| +8% | +$118K |
|
|
FOGO
2485
DELISTED
Fogo de Chao, Inc. Common Stock
FOGO
| $1.26M | ﹤0.01% |
+90,700
| New | +$1.35M |
|
2486
Parke Bancorp
PKBK
$411M
| $1.25M | ﹤0.01% |
67,614
+36,216
| +115% | +$626K |
|
|
JAX
2487
DELISTED
J. Alexander's Holdings, Inc.
JAX
| $1.25M | ﹤0.01% |
101,600
+34,200
| +51% | +$378K |
|
|
NVTR
2488
DELISTED
Nuvectra Corporation Common Stock
NVTR
| $1.24M | ﹤0.01% |
93,600
+30,100
| +47% | +$285K |
|
2489
AudioCodes
AUDC
$253M
| $1.24M | ﹤0.01% |
206,900
-122,500
| -37% | -$798K |
|
2490
Steven Madden
SHOO
$3.46B
| $1.24M | ﹤0.01% |
+46,467
| New | +$1.18M |
|
|
FSAM
2491
DELISTED
Fifth Street Asset Management Inc. Class A
FSAM
| $1.24M | ﹤0.01% |
254,800
-98,700
| -28% | -$411K |
|
|
MATR
2492
DELISTED
Mattersight Corp.
MATR
| $1.24M | ﹤0.01% |
484,400
+30,600
| +7% | +$89.3K |
|
|
GBL
2493
DELISTED
GAMCO Investors, Inc.
GBL
| $1.23M | ﹤0.01% |
41,700
+14,000
| +51% | +$408K |
|
|
OMED
2494
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $1.23M | ﹤0.01% |
369,596
-164,004
| -31% | -$680K |
|
|
ATAXZ
2495
DELISTED
AMERICA FIRST TAX EXEMT INV LP
ATAXZ
| $1.23M | ﹤0.01% |
206,924
-73,864
| -26% | -$439K |
|
2496
Madrigal Pharmaceuticals
MDGL
$11.6B
| $1.23M | ﹤0.01% |
75,387
+17,512
| +30% | +$274K |
|
2497
MakeMyTrip
MMYT
$5.71B
| $1.22M | ﹤0.01% |
36,467
-154,100
| -81% | -$5.35M |
|
2498
Cadiz
CDZI
$288M
| $1.22M | ﹤0.01% |
90,036
-39,164
| -30% | -$579K |
|
|
I
2499
DELISTED
INTELSAT S. A.
I
| $1.22M | ﹤0.01% |
397,100
+41,300
| +12% | +$138K |
|
|
CYRN
2500
DELISTED
CYREN Ltd.
CYRN
| $1.21M | ﹤0.01% |
29,612
-530
| -2% | -$22K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.